



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the editor

Re: Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity

María Ester Villacorta de la Cruz^{*}, Mery Juana Vilchez Osorio[†],
Leon Sandoval Segundo Ramos[†]

School of Human Medicine, San Juan Bautista Private University, Lima, Peru

ARTICLE INFO

Article history:

Received 17 May 2022

Received in revised form

3 June 2022

Accepted 3 June 2022

Available online 15 June 2022

Editor: L. Leibovici

To the Editor:

We read with great interest the article published by Ole Schmeltz Søgaard [1]. The study allowed us to comment on the limited information about the comorbidities that the authors assessed, especially on high blood pressure (HBP) as one of the most important.

High blood pressure is of particular interest because it is highly prevalent among adults and older adults. There have been concerns related to the use of renin-angiotensin system inhibitors in patients with hypertension infected with SARS-CoV-2 [2].

Many studies show that HBP, as well as diabetes, cerebrovascular disease, and ischemic heart disease, is markedly more frequent in patients who require critical care or die from COVID-19 [3]; therefore, HBP is considered a comorbidity that generates about half of the patients infected with COVID-19 admitted to hospitals [4]. The patients with chronic HBP frequently have target organ damage, which increases their susceptibility to SARS-CoV-2 and generates a high risk of unfavourable COVID-19-related outcomes.

Finally, although the publication informed us about the association between the serological response to COVID-19 vaccine and its durability, it is necessary to assess it in patients with the presence of HBP, as it is known to be a marker of worse prognosis amongst the patients with SARS-CoV-2 [2]. We suggest to take the patient's HBP into account while recording the evidence of its effects in the response of the COVID-19 vaccine [5].

Transparency declaration

The authors declare no conflict of interest.

Funding

This research has not received any scholarships from agencies in the public, commercial, or non-profit sectors.

Author's contributions

María E. Villacorta, proposed the idea and made the initial draft; Mery Vilchez, completed the draft and review; Segundo R. León, review the draft and approved the final version.

References

- [1] Søgaard OS, Reekie J, Johansen IS, Nielsen H, Benfield T, Wiese L, et al. Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study. *Clin Microbiol Infect* 2022;28:1126–33.
- [2] Drager LF, Pio-Abreu A, Lopes RD, Bortolotto LA. Is hypertension a real risk factor for poor prognosis in the COVID-19 pandemic? *Curr Hypertens Rep* 2020;22:43.

DOI of original article: <https://doi.org/10.1016/j.cmi.2022.03.003>.

^{*} Corresponding author. María Ester Villacorta de la Cruz, Paseo Los Franciscanos 452, Departamento 302, Callao, Peru.

E-mail address: maria.villacorta@upsjb.edu.pe (M.E. Villacorta de la Cruz).

[†] Mery Vilchez and Leon Segundo contributed equally to this work.

- [3] Salazar M, Barochiner J, Espeche W, Ennis I. COVID-19 and its relationship with hypertension and cardiovascular disease. *Hipertens y Riesgo Vasc* 2020;37:176–80.
- [4] An J, Zhou H, Luong TQ, Wei R, Mefford MT, Harrison TN, et al. Risk of hospitalization and mortality associated with uncontrolled blood pressure in patients with hypertension and COVID-19. *Int J Cardiol Cardiovasc Risk Prev* 2021;11:200117.
- [5] Tadic M, Saeed S, Grassi G, Taddei S, Mancia G, Cuspidi C. Hypertension and COVID-19: ongoing controversies. *Front Cardiovasc Med* 2021;8:6–11.